This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAlerisLife (FSQA) 주식 개요AlerisLife Inc. operates and manages senior living communities in the United States. 자세히 보기FSQA 펀더멘털 분석스노우플레이크 점수가치 평가3/6미래 성장2/6과거 실적0/6재무 건전성4/6배당0/6강점수익은 연간 68.88% 증가할 것으로 예상됩니다.동종업계 및 업계 대비 좋은 가치로 거래위험 분석cash runway 경력이 1년 미만입니다.지난 3개월 동안 주가 변동성이 German 시장과 비교했을 때 매우 높았습니다.의미 있는 시가총액이 없습니다(€41M)지난 1년 동안 주주가 희석되었습니다.+ 위험 1건 추가모든 위험 점검 보기FSQA Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW488,161 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeINBLROAG488,161 investors already sharing narrativesYour Fair Value€Current Price€1.21해당 없음내재 할인율Est. Revenue$PastFuture-60m2b2016201920222025202620282031Revenue US$2.2bEarnings US$155.1mAdvancedSet Fair ValueView all narrativesAlerisLife Inc. 경쟁사Maternus-KlinikenSymbol: XTRA:MAKMarket cap: €19.8mGesundheitswelt ChiemgauSymbol: MUN:JTH0Market cap: €21.3mMEDICLINSymbol: XTRA:MEDMarket cap: €189.1mLIMES SchlossklinikenSymbol: XTRA:LIKMarket cap: €163.9m가격 이력 및 성과AlerisLife 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가US$1.2152주 최고가US$2.1852주 최저가US$0.51베타0.961개월 변동0.83%3개월 변동77.94%1년 변동-40.10%3년 변동-47.84%5년 변동-88.25%IPO 이후 변동-96.64%최근 뉴스 및 업데이트Recent Insider Transactions • Mar 21Chairman & MD recently bought €27m worth of stockOn the 18th of March, Adam Portnoy bought around 22m shares on-market at roughly €1.23 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Adam's only on-market trade for the last 12 months.Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. MD, Secretary & Director Jennifer Clark was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Feb 05ABP Acquisition LLC entered into an agreement to acquire the remaining 93.7% stake in AlerisLife Inc. (NasdaqCM:ALR) from Diversified Healthcare Trust (NasdaqGS:DHC) and others for $41.2 million.ABP Acquisition LLC entered into an agreement to acquire the remaining 93.7% stake in AlerisLife Inc. (NasdaqCM:ALR) from Diversified Healthcare Trust (NasdaqGS:DHC) and others for $41.2 million on February 2, 2023. Under the terms of the transaction, ABP Acquisition will commence a tender offer to acquire all of the outstanding shares of AlerisLife at a price of $1.31 per share in cash. Post the transaction ABP Acquisition, ABP Trust and Adam D. Portnoy who currently own 6.1% stake of AlerisLife will own 100%. The transaction is subject to among other things, a number of shares being tendered in the tender offer that, together with the shares owned by ABP and its affiliates, represent a majority of ALR shares. Diversified Healthcare Trust which holds approximately 31.9% of the outstanding shares of ALR common stock, has also consented to the transaction and has agreed to tender its shares in the tender offer. Based on the recommendation of the special committee of Board, the Board of Directors of AlerisLife have unanimously approved the transaction. The transaction is expected to be completed in the first quarter of 2023. Faiz Ahmad of Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor to ABP Acquisition. Zachary Blume and Suni Sreepada of Ropes & Gray LLP acted as legal advisor to AlerisLife. Citigroup Global Markets Inc. acted as financial advisor to AlerisLife and provided fairness opinion to the Special Committee of AlerisLife.공시 • Nov 11AlerisLife Inc. Receives a Notification Letter from Nasdaq Regarding Minimum Bid PriceOn November 7, 2022, AlerisLife Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that, for the last 30 consecutive business days, the bid price of its shares of common stock, par value $0.01 per share (“common shares”), had closed below $1.00 per common share, which is the minimum required closing bid price for continued listing on Nasdaq pursuant to Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 days, or until May 8, 2023, to regain compliance with the minimum bid price continued listing standard. To regain compliance, the closing bid price of the common shares must meet or exceed $1.00 per common share for a minimum of 10 consecutive business days during the 180 calendar day grace period. If the Company is not in compliance by May 8, 2023, it may be afforded a second 180 calendar day grace period. To qualify for this additional time, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq with the exception of the minimum bid price requirement. If the Company does not regain compliance within the allotted period(s), including any extensions that it may receive, Nasdaq will provide notice that the common shares will be subject to delisting. The Company is monitoring the bid price of the common shares and is considering its options to achieve compliance with the minimum bid price continued listing standard.Breakeven Date Change • Nov 08No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$6.45m in 2024.Reported Earnings • Nov 04Third quarter 2022 earnings released: US$0.27 loss per share (vs US$0.32 loss in 3Q 2021)Third quarter 2022 results: US$0.27 loss per share (improved from US$0.32 loss in 3Q 2021). Revenue: US$182.7m (up 326% from 3Q 2021). Net loss: US$8.51m (loss narrowed 17% from 3Q 2021). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.더 많은 업데이트 보기Recent updatesRecent Insider Transactions • Mar 21Chairman & MD recently bought €27m worth of stockOn the 18th of March, Adam Portnoy bought around 22m shares on-market at roughly €1.23 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Adam's only on-market trade for the last 12 months.Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. MD, Secretary & Director Jennifer Clark was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Feb 05ABP Acquisition LLC entered into an agreement to acquire the remaining 93.7% stake in AlerisLife Inc. (NasdaqCM:ALR) from Diversified Healthcare Trust (NasdaqGS:DHC) and others for $41.2 million.ABP Acquisition LLC entered into an agreement to acquire the remaining 93.7% stake in AlerisLife Inc. (NasdaqCM:ALR) from Diversified Healthcare Trust (NasdaqGS:DHC) and others for $41.2 million on February 2, 2023. Under the terms of the transaction, ABP Acquisition will commence a tender offer to acquire all of the outstanding shares of AlerisLife at a price of $1.31 per share in cash. Post the transaction ABP Acquisition, ABP Trust and Adam D. Portnoy who currently own 6.1% stake of AlerisLife will own 100%. The transaction is subject to among other things, a number of shares being tendered in the tender offer that, together with the shares owned by ABP and its affiliates, represent a majority of ALR shares. Diversified Healthcare Trust which holds approximately 31.9% of the outstanding shares of ALR common stock, has also consented to the transaction and has agreed to tender its shares in the tender offer. Based on the recommendation of the special committee of Board, the Board of Directors of AlerisLife have unanimously approved the transaction. The transaction is expected to be completed in the first quarter of 2023. Faiz Ahmad of Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor to ABP Acquisition. Zachary Blume and Suni Sreepada of Ropes & Gray LLP acted as legal advisor to AlerisLife. Citigroup Global Markets Inc. acted as financial advisor to AlerisLife and provided fairness opinion to the Special Committee of AlerisLife.공시 • Nov 11AlerisLife Inc. Receives a Notification Letter from Nasdaq Regarding Minimum Bid PriceOn November 7, 2022, AlerisLife Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that, for the last 30 consecutive business days, the bid price of its shares of common stock, par value $0.01 per share (“common shares”), had closed below $1.00 per common share, which is the minimum required closing bid price for continued listing on Nasdaq pursuant to Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 days, or until May 8, 2023, to regain compliance with the minimum bid price continued listing standard. To regain compliance, the closing bid price of the common shares must meet or exceed $1.00 per common share for a minimum of 10 consecutive business days during the 180 calendar day grace period. If the Company is not in compliance by May 8, 2023, it may be afforded a second 180 calendar day grace period. To qualify for this additional time, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq with the exception of the minimum bid price requirement. If the Company does not regain compliance within the allotted period(s), including any extensions that it may receive, Nasdaq will provide notice that the common shares will be subject to delisting. The Company is monitoring the bid price of the common shares and is considering its options to achieve compliance with the minimum bid price continued listing standard.Breakeven Date Change • Nov 08No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$6.45m in 2024.Reported Earnings • Nov 04Third quarter 2022 earnings released: US$0.27 loss per share (vs US$0.32 loss in 3Q 2021)Third quarter 2022 results: US$0.27 loss per share (improved from US$0.32 loss in 3Q 2021). Revenue: US$182.7m (up 326% from 3Q 2021). Net loss: US$8.51m (loss narrowed 17% from 3Q 2021). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.공시 • Oct 18Alerislife Inc. Appoints Philip Benjamson as Senior Vice President and Chief Operating OfficerThe Board of Directors of AlerisLife Inc. (the “Company”) has appointed Philip Benjamson as Senior Vice President and Chief Operating Officer of the Company, effective October 17, 2022. Prior to joining the Company, Mr. Benjamson, 55, served as Vice President-Senior Housing Operations at Trinity Health Senior Communities since May 2021. Prior to Trinity Health Senior Communities, Mr. Benjamson served as Chief Operating Officer at Resort Lifestyle Communities from July 2018 to May 2021 and at Blake Management Group from December 2016 to July 2018. Prior to those roles, Mr. Benjamson held several leadership roles in sales and marketing at senior living companies. Mr. Benjamson holds a Bachelor of Arts in Organizational Development from the University of California, Davis. Mr. Benjamson has advised the Company that he has no arrangements or understandings with any other person pursuant to which he was appointed Senior Vice President and Chief Operating Officer. He also advised the Company that he has no family relationships with any director, executive officer or any person nominated or chosen by the Company to become a director or executive officer of the Company.공시 • Oct 06AlerisLife Inc. to Report Q3, 2022 Results on Nov 02, 2022AlerisLife Inc. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Nov 02, 2022공시 • Sep 20+ 1 more updateAlerisLife Inc. Announces Chief Financial Officer ChangesThe Board of Directors of AlerisLife Inc. has appointed Heather Pereira as Chief Financial Officer of the Company, effective September 19, 2022. Ms. Pereira succeeds Jeffrey C. Leer, who will continue to serve as the Company’s President and Chief Executive Officer. Prior to joining the Company, Ms. Pereira, 47, held financial and accounting roles of increasing responsibility at Acushnet Holdings Corp. since 2004, including Vice President and Corporate Controller from May 2017 through August 2022 and Controller between May 2014 and May 2017. Prior to Acushnet, Ms. Pereira served as Accounting Manager at Cognos Incorporated from 2002 to 2004 and was an Associate at Arthur Andersen LLP from 2002 through 2004. Ms. Pereira is a certified public accountant and holds a Master of Science in Accountancy and a Master of Business Administration from Northeastern University.Breakeven Date Change • Aug 09No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$1.66m in 2024.Reported Earnings • Aug 05Second quarter 2022 earnings released: US$0.28 loss per share (vs US$0.39 loss in 2Q 2021)Second quarter 2022 results: US$0.28 loss per share (up from US$0.39 loss in 2Q 2021). Revenue: US$39.7m (down 15% from 2Q 2021). Net loss: US$8.81m (loss narrowed 28% from 2Q 2021). Over the next year, revenue is forecast to grow 389%, compared to a 2.7% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.공시 • Jul 07AlerisLife Inc. to Report Q2, 2022 Results on Aug 03, 2022AlerisLife Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 03, 2022Reported Earnings • May 05First quarter 2022 earnings released: US$0.31 loss per share (vs US$0.10 profit in 1Q 2021)First quarter 2022 results: US$0.31 loss per share (down from US$0.10 profit in 1Q 2021). Revenue: US$173.2m (up 243% from 1Q 2021). Net loss: US$9.73m (down 394% from profit in 1Q 2021). Over the next year, revenue is forecast to grow 902%, compared to a 5.7% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 124% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.공시 • May 03+ 1 more updateAlerisLife Inc. Announces Management ChangesAlerisLife Inc. announced that it has named Jeff Leer as Interim President, effective May 1, 2022. Mr. Leer has served as Executive Vice President, Chief Financial Officer and Treasurer of ALR since 2019 and will continue these responsibilities. Mr. Leer succeeds Katie Potter, who resigned as President and Chief Executive Officer, effective April 30, 2022. Prior to joining AlerisLife in 2019, Mr. Leer held senior accounting and finance positions at The RMR Group and its affiliates, including serving as Chief Financial Officer and Treasurer of Office Properties Income Trust.Breakeven Date Change • Apr 27Forecast breakeven date pushed back to 2024The 2 analysts covering AlerisLife previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 57% per year to 2023. The company is expected to make a profit of US$7.23m in 2024. Average annual earnings growth of 80% is required to achieve expected profit on schedule.Breakeven Date Change • Apr 07Forecast breakeven date pushed back to 2024The 2 analysts covering AlerisLife previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 57% per year to 2023. The company is expected to make a profit of US$7.23m in 2024. Average annual earnings growth of 80% is required to achieve expected profit on schedule.공시 • Apr 07AlerisLife Inc., Annual General Meeting, Jun 07, 2022AlerisLife Inc., Annual General Meeting, Jun 07, 2022, at 09:30 US Eastern Standard Time. Agenda: To consider the election of the Director nominees to Board of Directors; to consider the approval of the second amended and restated 2014 Equity Compensation Plan; to ratify the appointment of Deloitte & Touche LLP as independent auditors to serve for the 2022 fiscal year; and to transact such other business as may properly come before the meeting and at any postponements or adjournments of the meeting.공시 • Apr 06AlerisLife Inc. to Report Q1, 2022 Results on May 03, 2022AlerisLife Inc. announced that they will report Q1, 2022 results After-Market on May 03, 2022Recent Insider Transactions • Mar 05Insider recently bought €91k worth of stockOn the 1st of March, Lauren Cody bought around 40k shares on-market at roughly €2.27 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Feb 25Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: US$0.95 loss per share (down from US$0.24 loss in FY 2020). Revenue: US$180.1m (down 19% from FY 2020). Net loss: US$29.9m (loss widened 294% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 329%, compared to a 4.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.공시 • Feb 02AlerisLife Inc. to Report Q4, 2021 Results on Feb 23, 2022AlerisLife Inc. announced that they will report Q4, 2021 results After-Market on Feb 23, 2022Reported Earnings • Nov 05Third quarter 2021 earnings released: US$0.32 loss per share (vs US$0.12 profit in 3Q 2020)The company reported a decent third quarter result with improved revenues, although earnings and control over costs were weaker. Third quarter 2021 results: Revenue: US$225.8m (up 311% from 3Q 2020). Net loss: US$10.2m (down 375% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Breakeven Date Change • Sep 23Forecast to breakeven in 2022The 2 analysts covering Five Star Senior Living expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$2.15m in 2022. Average annual earnings growth of 120% is required to achieve expected profit on schedule.Reported Earnings • Aug 06Second quarter 2021 earnings released: US$0.39 loss per share (vs US$0.095 profit in 2Q 2020)The company reported a decent second quarter result with improved revenues, although earnings and control over costs were weaker. Second quarter 2021 results: Revenue: US$258.6m (up 374% from 2Q 2020). Net loss: US$12.3m (down US$15.3m from profit in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.Breakeven Date Change • Aug 06Forecast breakeven pushed back to 2022The 2 analysts covering Five Star Senior Living previously expected the company to break even in 2021. New consensus forecast suggests losses will reduce by 26% to 2021. The company is expected to make a profit of US$7.69m in 2022. Average annual earnings growth of 146% is required to achieve expected profit on schedule.공시 • Jun 28+ 4 more updatesFive Star Senior Living Inc.(NasdaqCM:FVE) dropped from Russell 3000E Value IndexFive Star Senior Living Inc.(NasdaqCM:FVE) dropped from Russell 3000E Value IndexValuation Update With 7 Day Price Move • May 12Investor sentiment improved over the past weekAfter last week's 18% share price gain to US$5.10, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 28x in the Healthcare industry in Germany. Total loss to shareholders of 49% over the past three years.Reported Earnings • May 07First quarter 2021 earnings released: EPS US$0.10 (vs US$0.55 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$276.9m (up 366% from 1Q 2020). Net income: US$3.32m (up US$20.5m from 1Q 2020). Profit margin: 1.2% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Mar 04New 90-day low: €5.20The company is down 1.0% from its price of €5.25 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is down 9.0% over the same period.Executive Departure • Mar 02Chief Accounting Officer has left the companyOn the 23rd of February, Ellen Snow's tenure as Chief Accounting Officer ended after 1.5 years in the role. As of December 2020, Ellen personally held only 2.50k shares (€14k worth at the time). Ellen is the only executive to leave the company over the last 12 months.Reported Earnings • Feb 27Full year 2020 earnings released: US$0.24 loss per share (vs US$3.99 loss in FY 2019)The company reported a soft full year result with weaker revenues and control over costs, although losses reduced. Full year 2020 results: Revenue: US$221.9m (down 80% from FY 2019). Net loss: US$7.59m (loss narrowed 62% from FY 2019). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to US$6.75, the stock is trading at a trailing P/E ratio of 38.3x, up from the previous P/E ratio of 32.9x. This compares to an average P/E of 19x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 44%.Is New 90 Day High Low • Feb 06New 90-day high: €6.75The company is up 70% from its price of €3.98 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 7.0% over the same period.공시 • Feb 02Five Star Senior Living Inc. Partners with CVS to Administer Vaccines to Shop Community Residents and Staff, Which Commenced in December 2020Five Star Senior Living Inc. has partnered with CVS to administer vaccines to SHOP community residents and staff, which commenced in December 2020. DHC expects vaccination clinics for SHOP community residents and staff to be substantially complete by the end of the first quarter of 2021. As it pertains to DHC’s SHOP segment, as of January 29, 2021. Approximately 18,000 total residents and staff, or more than 65% of residents and more than 30% of staff at DHC’s SHOP communities, have received vaccinations. This includes over 2,000 residents and staff who have received both doses of the vaccine; Approximately 93% of DHC’s SHOP communities are currently open to new admissions; and; Approximately 3.5% of DHC’s total SHOP community residents have or have had active cases of COVID-19, and approximately 67% of those who have tested positive for COVID-19 during the pandemic have since recovered, as defined by CDC guidelines. For the months ended September 30, October 31, November 30 and December 31, 2020, average occupancies in DHC’s SHOP segment were 74.5%, 73.8%, 72.5%, and 70.7%, respectively. Although occupancy has declined because of reduced move-ins by residents, sales leads have increased substantially since the end of 2020. The rolling four-week average sales leads as of January 24, 2021 were 83% higher than the rolling four-week average sales leads at the beginning of the fourth quarter of 2020.공시 • Jan 29Five Star Senior Living Inc. to Report Q4, 2020 Results on Feb 24, 2021Five Star Senior Living Inc. announced that they will report Q4, 2020 results After-Market on Feb 24, 2021Valuation Update With 7 Day Price Move • Dec 17Investor sentiment improved over the past weekAfter last week's 16% share price gain to US$6.65, the stock is trading at a trailing P/E ratio of 35.7x, up from the previous P/E ratio of 30.9x. This compares to an average P/E of 17x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 46%.Is New 90 Day High Low • Dec 12New 90-day high: €6.05The company is up 33% from its price of €4.54 on 11 September 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 4.0% over the same period.Valuation Update With 7 Day Price Move • Dec 08Market bids up stock over the past weekAfter last week's 19% share price gain to US$5.85, the stock is trading at a trailing P/E ratio of 31.4x, up from the previous P/E ratio of 26.3x. This compares to an average P/E of 18x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 55%.Valuation Update With 7 Day Price Move • Dec 05Market bids up stock over the past weekAfter last week's 15% share price gain to US$5.65, the stock is trading at a trailing P/E ratio of 31.7x, up from the previous P/E ratio of 27.5x. This compares to an average P/E of 18x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 55%.Is New 90 Day High Low • Nov 24New 90-day high: €4.60The company is up 5.0% from its price of €4.38 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period.Valuation Update With 7 Day Price Move • Nov 12Market bids up stock over the past weekAfter last week's 18% share price gain to US$4.42, the stock is trading at a trailing P/E ratio of 23x, up from the previous P/E ratio of 19.5x. This compares to an average P/E of 19x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 70%.Reported Earnings • Nov 07Third quarter 2020 earnings released: EPS US$0.12The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$295.3m (up 7.7% from 3Q 2019). Net income: US$3.72m (up US$10.8m from 3Q 2019). Profit margin: 1.3% (up from net loss in 3Q 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Oct 29New 90-day low: €3.74The company is down 1.0% from its price of €3.78 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 15% over the same period.공시 • Oct 10Five Star Senior Living Inc. to Report Q3, 2020 Results on Nov 05, 2020Five Star Senior Living Inc. announced that they will report Q3, 2020 results at 9:00 AM, Eastern Standard Time on Nov 05, 2020공시 • Jul 10Five Star Senior Living Inc. to Report Q2, 2020 Results on Aug 06, 2020Five Star Senior Living Inc. announced that they will report Q2, 2020 results at 9:00 AM, Eastern Standard Time on Aug 06, 2020주주 수익률FSQADE HealthcareDE 시장7D0.8%-1.2%-0.2%1Y-40.1%-9.4%1.3%전체 주주 수익률 보기수익률 대 산업: FSQA은 지난 1년 동안 -9.4%의 수익을 기록한 German Healthcare 산업보다 저조한 성과를 냈습니다.수익률 대 시장: FSQA은 지난 1년 동안 1.3%를 기록한 German 시장보다 저조한 성과를 냈습니다.주가 변동성Is FSQA's price volatile compared to industry and market?FSQA volatilityFSQA Average Weekly Movement20.9%Healthcare Industry Average Movement5.4%Market Average Movement5.6%10% most volatile stocks in DE Market13.3%10% least volatile stocks in DE Market2.8%안정적인 주가: FSQA의 주가는 지난 3개월 동안 German 시장보다 변동성이 컸습니다.시간에 따른 변동성: FSQA의 주간 변동성은 지난 1년간 14%에서 21%로 증가했습니다.회사 소개설립직원 수CEO웹사이트20018,600Jeff Leerwww.alerislife.com더 보기AlerisLife Inc. 기초 지표 요약AlerisLife의 순이익과 매출은 시가총액과 어떻게 비교됩니까?FSQA 기초 통계시가총액€41.18m순이익 (TTM)-€35.24m매출 (TTM)€148.96m0.3x주가매출비율(P/S)-1.2x주가수익비율(P/E)FSQA는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표FSQA 손익계산서 (TTM)매출US$159.70m매출원가US$90.05m총이익US$69.65m기타 비용US$107.43m순이익-US$37.78m최근 보고된 실적Sep 30, 2022다음 실적 발표일해당 없음주당순이익(EPS)-1.13총이익률43.61%순이익률-23.66%부채/자본 비율43.8%FSQA의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/03/21 02:35종가2023/03/17 00:00수익2022/09/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스AlerisLife Inc.는 10명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Bryan MaherB. Riley Securities, Inc.Joseph FranceCantor Fitzgerald & Co.Peter MartinCitizens JMP Securities, LLC7명의 분석가 더 보기
Recent Insider Transactions • Mar 21Chairman & MD recently bought €27m worth of stockOn the 18th of March, Adam Portnoy bought around 22m shares on-market at roughly €1.23 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Adam's only on-market trade for the last 12 months.
Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. MD, Secretary & Director Jennifer Clark was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Feb 05ABP Acquisition LLC entered into an agreement to acquire the remaining 93.7% stake in AlerisLife Inc. (NasdaqCM:ALR) from Diversified Healthcare Trust (NasdaqGS:DHC) and others for $41.2 million.ABP Acquisition LLC entered into an agreement to acquire the remaining 93.7% stake in AlerisLife Inc. (NasdaqCM:ALR) from Diversified Healthcare Trust (NasdaqGS:DHC) and others for $41.2 million on February 2, 2023. Under the terms of the transaction, ABP Acquisition will commence a tender offer to acquire all of the outstanding shares of AlerisLife at a price of $1.31 per share in cash. Post the transaction ABP Acquisition, ABP Trust and Adam D. Portnoy who currently own 6.1% stake of AlerisLife will own 100%. The transaction is subject to among other things, a number of shares being tendered in the tender offer that, together with the shares owned by ABP and its affiliates, represent a majority of ALR shares. Diversified Healthcare Trust which holds approximately 31.9% of the outstanding shares of ALR common stock, has also consented to the transaction and has agreed to tender its shares in the tender offer. Based on the recommendation of the special committee of Board, the Board of Directors of AlerisLife have unanimously approved the transaction. The transaction is expected to be completed in the first quarter of 2023. Faiz Ahmad of Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor to ABP Acquisition. Zachary Blume and Suni Sreepada of Ropes & Gray LLP acted as legal advisor to AlerisLife. Citigroup Global Markets Inc. acted as financial advisor to AlerisLife and provided fairness opinion to the Special Committee of AlerisLife.
공시 • Nov 11AlerisLife Inc. Receives a Notification Letter from Nasdaq Regarding Minimum Bid PriceOn November 7, 2022, AlerisLife Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that, for the last 30 consecutive business days, the bid price of its shares of common stock, par value $0.01 per share (“common shares”), had closed below $1.00 per common share, which is the minimum required closing bid price for continued listing on Nasdaq pursuant to Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 days, or until May 8, 2023, to regain compliance with the minimum bid price continued listing standard. To regain compliance, the closing bid price of the common shares must meet or exceed $1.00 per common share for a minimum of 10 consecutive business days during the 180 calendar day grace period. If the Company is not in compliance by May 8, 2023, it may be afforded a second 180 calendar day grace period. To qualify for this additional time, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq with the exception of the minimum bid price requirement. If the Company does not regain compliance within the allotted period(s), including any extensions that it may receive, Nasdaq will provide notice that the common shares will be subject to delisting. The Company is monitoring the bid price of the common shares and is considering its options to achieve compliance with the minimum bid price continued listing standard.
Breakeven Date Change • Nov 08No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$6.45m in 2024.
Reported Earnings • Nov 04Third quarter 2022 earnings released: US$0.27 loss per share (vs US$0.32 loss in 3Q 2021)Third quarter 2022 results: US$0.27 loss per share (improved from US$0.32 loss in 3Q 2021). Revenue: US$182.7m (up 326% from 3Q 2021). Net loss: US$8.51m (loss narrowed 17% from 3Q 2021). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Mar 21Chairman & MD recently bought €27m worth of stockOn the 18th of March, Adam Portnoy bought around 22m shares on-market at roughly €1.23 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Adam's only on-market trade for the last 12 months.
Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. MD, Secretary & Director Jennifer Clark was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Feb 05ABP Acquisition LLC entered into an agreement to acquire the remaining 93.7% stake in AlerisLife Inc. (NasdaqCM:ALR) from Diversified Healthcare Trust (NasdaqGS:DHC) and others for $41.2 million.ABP Acquisition LLC entered into an agreement to acquire the remaining 93.7% stake in AlerisLife Inc. (NasdaqCM:ALR) from Diversified Healthcare Trust (NasdaqGS:DHC) and others for $41.2 million on February 2, 2023. Under the terms of the transaction, ABP Acquisition will commence a tender offer to acquire all of the outstanding shares of AlerisLife at a price of $1.31 per share in cash. Post the transaction ABP Acquisition, ABP Trust and Adam D. Portnoy who currently own 6.1% stake of AlerisLife will own 100%. The transaction is subject to among other things, a number of shares being tendered in the tender offer that, together with the shares owned by ABP and its affiliates, represent a majority of ALR shares. Diversified Healthcare Trust which holds approximately 31.9% of the outstanding shares of ALR common stock, has also consented to the transaction and has agreed to tender its shares in the tender offer. Based on the recommendation of the special committee of Board, the Board of Directors of AlerisLife have unanimously approved the transaction. The transaction is expected to be completed in the first quarter of 2023. Faiz Ahmad of Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor to ABP Acquisition. Zachary Blume and Suni Sreepada of Ropes & Gray LLP acted as legal advisor to AlerisLife. Citigroup Global Markets Inc. acted as financial advisor to AlerisLife and provided fairness opinion to the Special Committee of AlerisLife.
공시 • Nov 11AlerisLife Inc. Receives a Notification Letter from Nasdaq Regarding Minimum Bid PriceOn November 7, 2022, AlerisLife Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that, for the last 30 consecutive business days, the bid price of its shares of common stock, par value $0.01 per share (“common shares”), had closed below $1.00 per common share, which is the minimum required closing bid price for continued listing on Nasdaq pursuant to Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 days, or until May 8, 2023, to regain compliance with the minimum bid price continued listing standard. To regain compliance, the closing bid price of the common shares must meet or exceed $1.00 per common share for a minimum of 10 consecutive business days during the 180 calendar day grace period. If the Company is not in compliance by May 8, 2023, it may be afforded a second 180 calendar day grace period. To qualify for this additional time, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq with the exception of the minimum bid price requirement. If the Company does not regain compliance within the allotted period(s), including any extensions that it may receive, Nasdaq will provide notice that the common shares will be subject to delisting. The Company is monitoring the bid price of the common shares and is considering its options to achieve compliance with the minimum bid price continued listing standard.
Breakeven Date Change • Nov 08No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$6.45m in 2024.
Reported Earnings • Nov 04Third quarter 2022 earnings released: US$0.27 loss per share (vs US$0.32 loss in 3Q 2021)Third quarter 2022 results: US$0.27 loss per share (improved from US$0.32 loss in 3Q 2021). Revenue: US$182.7m (up 326% from 3Q 2021). Net loss: US$8.51m (loss narrowed 17% from 3Q 2021). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
공시 • Oct 18Alerislife Inc. Appoints Philip Benjamson as Senior Vice President and Chief Operating OfficerThe Board of Directors of AlerisLife Inc. (the “Company”) has appointed Philip Benjamson as Senior Vice President and Chief Operating Officer of the Company, effective October 17, 2022. Prior to joining the Company, Mr. Benjamson, 55, served as Vice President-Senior Housing Operations at Trinity Health Senior Communities since May 2021. Prior to Trinity Health Senior Communities, Mr. Benjamson served as Chief Operating Officer at Resort Lifestyle Communities from July 2018 to May 2021 and at Blake Management Group from December 2016 to July 2018. Prior to those roles, Mr. Benjamson held several leadership roles in sales and marketing at senior living companies. Mr. Benjamson holds a Bachelor of Arts in Organizational Development from the University of California, Davis. Mr. Benjamson has advised the Company that he has no arrangements or understandings with any other person pursuant to which he was appointed Senior Vice President and Chief Operating Officer. He also advised the Company that he has no family relationships with any director, executive officer or any person nominated or chosen by the Company to become a director or executive officer of the Company.
공시 • Oct 06AlerisLife Inc. to Report Q3, 2022 Results on Nov 02, 2022AlerisLife Inc. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Nov 02, 2022
공시 • Sep 20+ 1 more updateAlerisLife Inc. Announces Chief Financial Officer ChangesThe Board of Directors of AlerisLife Inc. has appointed Heather Pereira as Chief Financial Officer of the Company, effective September 19, 2022. Ms. Pereira succeeds Jeffrey C. Leer, who will continue to serve as the Company’s President and Chief Executive Officer. Prior to joining the Company, Ms. Pereira, 47, held financial and accounting roles of increasing responsibility at Acushnet Holdings Corp. since 2004, including Vice President and Corporate Controller from May 2017 through August 2022 and Controller between May 2014 and May 2017. Prior to Acushnet, Ms. Pereira served as Accounting Manager at Cognos Incorporated from 2002 to 2004 and was an Associate at Arthur Andersen LLP from 2002 through 2004. Ms. Pereira is a certified public accountant and holds a Master of Science in Accountancy and a Master of Business Administration from Northeastern University.
Breakeven Date Change • Aug 09No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$1.66m in 2024.
Reported Earnings • Aug 05Second quarter 2022 earnings released: US$0.28 loss per share (vs US$0.39 loss in 2Q 2021)Second quarter 2022 results: US$0.28 loss per share (up from US$0.39 loss in 2Q 2021). Revenue: US$39.7m (down 15% from 2Q 2021). Net loss: US$8.81m (loss narrowed 28% from 2Q 2021). Over the next year, revenue is forecast to grow 389%, compared to a 2.7% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
공시 • Jul 07AlerisLife Inc. to Report Q2, 2022 Results on Aug 03, 2022AlerisLife Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 03, 2022
Reported Earnings • May 05First quarter 2022 earnings released: US$0.31 loss per share (vs US$0.10 profit in 1Q 2021)First quarter 2022 results: US$0.31 loss per share (down from US$0.10 profit in 1Q 2021). Revenue: US$173.2m (up 243% from 1Q 2021). Net loss: US$9.73m (down 394% from profit in 1Q 2021). Over the next year, revenue is forecast to grow 902%, compared to a 5.7% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 124% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
공시 • May 03+ 1 more updateAlerisLife Inc. Announces Management ChangesAlerisLife Inc. announced that it has named Jeff Leer as Interim President, effective May 1, 2022. Mr. Leer has served as Executive Vice President, Chief Financial Officer and Treasurer of ALR since 2019 and will continue these responsibilities. Mr. Leer succeeds Katie Potter, who resigned as President and Chief Executive Officer, effective April 30, 2022. Prior to joining AlerisLife in 2019, Mr. Leer held senior accounting and finance positions at The RMR Group and its affiliates, including serving as Chief Financial Officer and Treasurer of Office Properties Income Trust.
Breakeven Date Change • Apr 27Forecast breakeven date pushed back to 2024The 2 analysts covering AlerisLife previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 57% per year to 2023. The company is expected to make a profit of US$7.23m in 2024. Average annual earnings growth of 80% is required to achieve expected profit on schedule.
Breakeven Date Change • Apr 07Forecast breakeven date pushed back to 2024The 2 analysts covering AlerisLife previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 57% per year to 2023. The company is expected to make a profit of US$7.23m in 2024. Average annual earnings growth of 80% is required to achieve expected profit on schedule.
공시 • Apr 07AlerisLife Inc., Annual General Meeting, Jun 07, 2022AlerisLife Inc., Annual General Meeting, Jun 07, 2022, at 09:30 US Eastern Standard Time. Agenda: To consider the election of the Director nominees to Board of Directors; to consider the approval of the second amended and restated 2014 Equity Compensation Plan; to ratify the appointment of Deloitte & Touche LLP as independent auditors to serve for the 2022 fiscal year; and to transact such other business as may properly come before the meeting and at any postponements or adjournments of the meeting.
공시 • Apr 06AlerisLife Inc. to Report Q1, 2022 Results on May 03, 2022AlerisLife Inc. announced that they will report Q1, 2022 results After-Market on May 03, 2022
Recent Insider Transactions • Mar 05Insider recently bought €91k worth of stockOn the 1st of March, Lauren Cody bought around 40k shares on-market at roughly €2.27 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Feb 25Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: US$0.95 loss per share (down from US$0.24 loss in FY 2020). Revenue: US$180.1m (down 19% from FY 2020). Net loss: US$29.9m (loss widened 294% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 329%, compared to a 4.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
공시 • Feb 02AlerisLife Inc. to Report Q4, 2021 Results on Feb 23, 2022AlerisLife Inc. announced that they will report Q4, 2021 results After-Market on Feb 23, 2022
Reported Earnings • Nov 05Third quarter 2021 earnings released: US$0.32 loss per share (vs US$0.12 profit in 3Q 2020)The company reported a decent third quarter result with improved revenues, although earnings and control over costs were weaker. Third quarter 2021 results: Revenue: US$225.8m (up 311% from 3Q 2020). Net loss: US$10.2m (down 375% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Sep 23Forecast to breakeven in 2022The 2 analysts covering Five Star Senior Living expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$2.15m in 2022. Average annual earnings growth of 120% is required to achieve expected profit on schedule.
Reported Earnings • Aug 06Second quarter 2021 earnings released: US$0.39 loss per share (vs US$0.095 profit in 2Q 2020)The company reported a decent second quarter result with improved revenues, although earnings and control over costs were weaker. Second quarter 2021 results: Revenue: US$258.6m (up 374% from 2Q 2020). Net loss: US$12.3m (down US$15.3m from profit in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Aug 06Forecast breakeven pushed back to 2022The 2 analysts covering Five Star Senior Living previously expected the company to break even in 2021. New consensus forecast suggests losses will reduce by 26% to 2021. The company is expected to make a profit of US$7.69m in 2022. Average annual earnings growth of 146% is required to achieve expected profit on schedule.
공시 • Jun 28+ 4 more updatesFive Star Senior Living Inc.(NasdaqCM:FVE) dropped from Russell 3000E Value IndexFive Star Senior Living Inc.(NasdaqCM:FVE) dropped from Russell 3000E Value Index
Valuation Update With 7 Day Price Move • May 12Investor sentiment improved over the past weekAfter last week's 18% share price gain to US$5.10, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 28x in the Healthcare industry in Germany. Total loss to shareholders of 49% over the past three years.
Reported Earnings • May 07First quarter 2021 earnings released: EPS US$0.10 (vs US$0.55 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$276.9m (up 366% from 1Q 2020). Net income: US$3.32m (up US$20.5m from 1Q 2020). Profit margin: 1.2% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Mar 04New 90-day low: €5.20The company is down 1.0% from its price of €5.25 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is down 9.0% over the same period.
Executive Departure • Mar 02Chief Accounting Officer has left the companyOn the 23rd of February, Ellen Snow's tenure as Chief Accounting Officer ended after 1.5 years in the role. As of December 2020, Ellen personally held only 2.50k shares (€14k worth at the time). Ellen is the only executive to leave the company over the last 12 months.
Reported Earnings • Feb 27Full year 2020 earnings released: US$0.24 loss per share (vs US$3.99 loss in FY 2019)The company reported a soft full year result with weaker revenues and control over costs, although losses reduced. Full year 2020 results: Revenue: US$221.9m (down 80% from FY 2019). Net loss: US$7.59m (loss narrowed 62% from FY 2019). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to US$6.75, the stock is trading at a trailing P/E ratio of 38.3x, up from the previous P/E ratio of 32.9x. This compares to an average P/E of 19x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 44%.
Is New 90 Day High Low • Feb 06New 90-day high: €6.75The company is up 70% from its price of €3.98 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 7.0% over the same period.
공시 • Feb 02Five Star Senior Living Inc. Partners with CVS to Administer Vaccines to Shop Community Residents and Staff, Which Commenced in December 2020Five Star Senior Living Inc. has partnered with CVS to administer vaccines to SHOP community residents and staff, which commenced in December 2020. DHC expects vaccination clinics for SHOP community residents and staff to be substantially complete by the end of the first quarter of 2021. As it pertains to DHC’s SHOP segment, as of January 29, 2021. Approximately 18,000 total residents and staff, or more than 65% of residents and more than 30% of staff at DHC’s SHOP communities, have received vaccinations. This includes over 2,000 residents and staff who have received both doses of the vaccine; Approximately 93% of DHC’s SHOP communities are currently open to new admissions; and; Approximately 3.5% of DHC’s total SHOP community residents have or have had active cases of COVID-19, and approximately 67% of those who have tested positive for COVID-19 during the pandemic have since recovered, as defined by CDC guidelines. For the months ended September 30, October 31, November 30 and December 31, 2020, average occupancies in DHC’s SHOP segment were 74.5%, 73.8%, 72.5%, and 70.7%, respectively. Although occupancy has declined because of reduced move-ins by residents, sales leads have increased substantially since the end of 2020. The rolling four-week average sales leads as of January 24, 2021 were 83% higher than the rolling four-week average sales leads at the beginning of the fourth quarter of 2020.
공시 • Jan 29Five Star Senior Living Inc. to Report Q4, 2020 Results on Feb 24, 2021Five Star Senior Living Inc. announced that they will report Q4, 2020 results After-Market on Feb 24, 2021
Valuation Update With 7 Day Price Move • Dec 17Investor sentiment improved over the past weekAfter last week's 16% share price gain to US$6.65, the stock is trading at a trailing P/E ratio of 35.7x, up from the previous P/E ratio of 30.9x. This compares to an average P/E of 17x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 46%.
Is New 90 Day High Low • Dec 12New 90-day high: €6.05The company is up 33% from its price of €4.54 on 11 September 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 4.0% over the same period.
Valuation Update With 7 Day Price Move • Dec 08Market bids up stock over the past weekAfter last week's 19% share price gain to US$5.85, the stock is trading at a trailing P/E ratio of 31.4x, up from the previous P/E ratio of 26.3x. This compares to an average P/E of 18x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 55%.
Valuation Update With 7 Day Price Move • Dec 05Market bids up stock over the past weekAfter last week's 15% share price gain to US$5.65, the stock is trading at a trailing P/E ratio of 31.7x, up from the previous P/E ratio of 27.5x. This compares to an average P/E of 18x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 55%.
Is New 90 Day High Low • Nov 24New 90-day high: €4.60The company is up 5.0% from its price of €4.38 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period.
Valuation Update With 7 Day Price Move • Nov 12Market bids up stock over the past weekAfter last week's 18% share price gain to US$4.42, the stock is trading at a trailing P/E ratio of 23x, up from the previous P/E ratio of 19.5x. This compares to an average P/E of 19x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 70%.
Reported Earnings • Nov 07Third quarter 2020 earnings released: EPS US$0.12The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$295.3m (up 7.7% from 3Q 2019). Net income: US$3.72m (up US$10.8m from 3Q 2019). Profit margin: 1.3% (up from net loss in 3Q 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Oct 29New 90-day low: €3.74The company is down 1.0% from its price of €3.78 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 15% over the same period.
공시 • Oct 10Five Star Senior Living Inc. to Report Q3, 2020 Results on Nov 05, 2020Five Star Senior Living Inc. announced that they will report Q3, 2020 results at 9:00 AM, Eastern Standard Time on Nov 05, 2020
공시 • Jul 10Five Star Senior Living Inc. to Report Q2, 2020 Results on Aug 06, 2020Five Star Senior Living Inc. announced that they will report Q2, 2020 results at 9:00 AM, Eastern Standard Time on Aug 06, 2020
